Technical Analysis for FOMX - Foamix Pharmaceuticals Ltd.

Grade Last Price % Change Price Change
grade D 3.89 2.10% 0.08
FOMX closed up 2.1 percent on Wednesday, March 20, 2019, on 40 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical FOMX trend table...

Date Alert Name Type % Chg
Mar 20 NR7 Range Contraction 0.00%
Mar 19 MACD Bearish Signal Line Cross Bearish 2.10%
Mar 19 20 DMA Support Bullish 2.10%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.10%
Mar 19 Doji - Bullish? Reversal 2.10%
Mar 19 Wide Bands Range Expansion 2.10%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.64%
Mar 18 Wide Bands Range Expansion 2.64%
Mar 18 Down 3 Days in a Row Weakness 2.64%
Mar 18 Down 4 Days in a Row Weakness 2.64%

Older signals for FOMX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. Its lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. The company is also developing FMX101 to treat rosacea; and FDX104 to treat chemotherapy-induced rashes, as well as early-stage foam formulations of various drugs for the treatment of dermatological indications, including antibacterial drugs, antifungal drugs, corticosteroids, and immunomodulators. Foamix Pharmaceuticals Ltd. has development and license agreements Bayer AG, Merz Pharmaceuticals, LLC, Actavis plc, Prestium Pharma, Inc. and Arkin Holdings Ltd., and others. It has operations in the United States, Germany, and Israel. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Pharmaceutical Chemotherapy Acne Rosacea Anti Acne Preparations Impetigo
Is FOMX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.6
52 Week Low 3.21
Average Volume 386,660
200-Day Moving Average 4.6989
50-Day Moving Average 3.7316
20-Day Moving Average 3.7965
10-Day Moving Average 4.02
Average True Range 0.2154
ADX 19.93
+DI 22.4597
-DI 19.0217
Chandelier Exit (Long, 3 ATRs ) 3.8338
Chandelier Exit (Short, 3 ATRs ) 3.8562
Upper Bollinger Band 4.3622
Lower Bollinger Band 3.2308
Percent B (%b) 0.58
BandWidth 29.801133
MACD Line 0.0768
MACD Signal Line 0.0846
MACD Histogram -0.0078
Fundamentals Value
Market Cap 145.59 Million
Num Shares 37.4 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -2.92
Price-to-Sales 40.32
Price-to-Book 2.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.06
Resistance 3 (R3) 4.05 3.98 4.03
Resistance 2 (R2) 3.98 3.94 3.99 4.02
Resistance 1 (R1) 3.94 3.92 3.96 3.95 4.01
Pivot Point 3.87 3.87 3.89 3.88 3.87
Support 1 (S1) 3.83 3.83 3.85 3.84 3.77
Support 2 (S2) 3.76 3.81 3.77 3.76
Support 3 (S3) 3.72 3.76 3.75
Support 4 (S4) 3.73